What is Spiracur?
Headquartered in Sunnyvale, California, Spiracur emerged from the Stanford University Biodesign Innovation Program in 2007. The company specializes in the development of advanced wound care technologies, most notably the SNaP Therapy System and the ciSNaP Closed Incision System. By focusing on controlled tension relief and patient-centric design, Spiracur addresses the limitations of cumbersome, legacy negative pressure wound therapies. Its products, which have secured both FDA 510(k) clearance and CE Mark approval, represent a significant shift toward mechanically powered, portable, and efficient surgical recovery tools that enhance healing outcomes for both chronic and acute wound patients.
How much funding has Spiracur raised?
Spiracur has raised a total of $75.5M across 4 funding rounds:
Series A
$4.2M
Series B
$20.3M
Unspecified
$35M
Debt
$16M
Series A (2007): $4.2M, investors not publicly disclosed
Series B (2009): $20.3M led by De Novo Ventures, Kleiner Perkins Caufield & Byers, and New Leaf Venture Partners
Unspecified (2011): $35M supported by De Novo Ventures, Kleiner Perkins Caufield & Byers, New Leaf Venture Partners, Maverick Capital, and Pinnacle Ventures
Debt (2014): $16M featuring GE Capital
Key Investors in Spiracur
Kleiner Perkins Caufield & Byers
Kleiner Perkins is a Menlo Park-based venture capital firm that raises dedicated funds and invests in early and growth-stage technology and life-science companies, backing founders across consumer, enterprise, healthcare, and climate/hard tech with capital and operational support from seed through IPO or acquisition.
New Leaf Venture Partners
New Venture Partners LLC is a global venture capital firm dedicated to corporate technology spinouts, providing a systematic process for commercializing innovations and bridging the gap between R&D labs and market-ready ventures.
GE Capital
A division of the global infrastructure and technology conglomerate, GE Capital provides specialized financial solutions and industrial expertise to support the growth of high-impact healthcare and technology enterprises.
What's next for Spiracur?
As Spiracur continues to refine its commercial footprint, the strategic focus remains on the widespread adoption of its proprietary mechanical platforms. The company's trajectory, supported by a diverse syndicate of venture capital and debt financing partners, suggests a transition toward broader market penetration and potential integration into standard surgical protocols. By leveraging its unique intellectual property, Spiracur is well-positioned to disrupt the traditional wound care market, offering clinicians a simplified, effective alternative that reduces operational complexity while maintaining high clinical standards for patient recovery.
See full Spiracur company page
